Androprostamine A: a unique antiprostate cancer agent

J Antibiot (Tokyo). 2021 Oct;74(10):717-725. doi: 10.1038/s41429-021-00449-8. Epub 2021 Jul 28.

Abstract

The androgen receptor (AR) is an important therapeutic target for all clinical states of prostate cancer. We screened cultured broths of microorganisms for their ability to suppress androgen-dependent growth of human prostate cancer LNCaP and VCaP cells without cytotoxicity. We have already identified androprostamine A (APA) from a Streptomyces culture broth as a functional inhibitor of AR. APA repressed R1881 (the synthetic androgen methyltrienolone)-induced androgen-regulated gene expression and dramatically inhibited R1881-induced prostate-specific antigen levels. However, APA did not act as an AR antagonist and did not inhibit AR transcriptional activity. Moreover, AS2405, an APA derivative, significantly inhibited the growth of VCaP cells in SCID mice upon oral administration.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / metabolism
  • Antineoplastic Agents / therapeutic use*
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Cinnamates / chemistry
  • Cinnamates / metabolism
  • Cinnamates / therapeutic use*
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • Male
  • Molecular Structure
  • Oligopeptides / chemistry
  • Oligopeptides / metabolism
  • Oligopeptides / therapeutic use*
  • Prostatic Neoplasms / drug therapy*
  • Streptomyces / metabolism

Substances

  • Antineoplastic Agents
  • Cinnamates
  • Oligopeptides
  • androprostamine A